Market Movers Today: Tetraphase Pharmaceuticals Inc (TTPH), Twilio Inc (TWLO), Genesco Inc. (GCO), Nektar Therapeutics (NKTR), and More
Tetraphase Pharmaceuticals Inc's Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to ace a late-stage trial.